Importantly, the role of systemic CD4 T cells has been emphasized in two recent studies conducted in lung cancer where the presence of functional CD4 Th1 cells in blood at the baseline (pre-existing immunity) proved to predict clinical response to anti-PD-1/PD-L1 immunotherapy [121,122]. Here, CD4 is linked to lung carcinoma.